← Oncology Approval Tracker

FDA DECISION ·

Romvimza

vimseltinib · Deciphera Pharmaceuticals

FDA approvalNew therapyTenosynovial giant cell tumor
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

For adults with symptomatic tenosynovial giant cell tumor when surgical removal could worsen physical function or cause severe morbidity.

LAMPGEN ANALYSIS

Why it matters

A CSF1R inhibitor offers systemic treatment for a symptomatic, generally nonmalignant joint tumor when surgery carries substantial risk.

What research teams should watch

Record the surgical assessment and use a consistent approach to tracking joint function, symptoms, and imaging.

PRIMARY RECORDS

Sources